Hopital Jeanne De Flandre
- Address
- Avenue Eugene Avinee, 59037 Lille, France
Congenital and Rare Pediatric Diseases
At Hopital Jeanne De Flandre, research in congenital, hereditary, and neonatal diseases focuses on rare conditions affecting children, including Duchenne Muscular Dystrophy and Hemolytic Disease of the Fetus and Newborn. These studies are designed to test new therapies and better understand how to improve outcomes in highly specialized pediatric care.
- Gene therapy approaches for Duchenne Muscular Dystrophy
- Preventing fetal anemia in Hemolytic Disease of the Fetus and Newborn
- Improving treatment options for rare inherited and neonatal disorders
These trials aim to expand safe, effective options for children and families facing serious genetic or early-life diseases.
Hemic and Lymphatic Disorders
Clinical trials in hemic and lymphatic diseases at this hospital in Lille include studies of anemia associated with chronic kidney disease, sickle cell disease, and several childhood blood cancers. The research is centered on evaluating treatments that may improve symptom control, reduce complications, and strengthen disease response.
- Anemia linked to chronic kidney disease in children and adolescents
- Vaso-occlusive crisis pain management in sickle cell disease
- Acute lymphoblastic leukemia, Hodgkin lymphoma, and anaplastic large cell lymphoma
These studies are helping assess new medicines and supportive care strategies for pediatric blood disorders and malignancies.
Immune System Diseases
Research in immune system diseases includes trials for pulmonary arterial hypertension and steroid-refractory acute graft-versus-host disease, both of which involve complex inflammatory and immune-driven processes. The main goal is to compare emerging therapies with current care and determine whether they can better control disease progression or improve response.
- Pulmonary arterial hypertension in children
- Acute graft-versus-host disease that does not respond to standard steroids
- Assessing treatment effectiveness and safety in difficult-to-manage immune conditions
These trials reflect a strong interest in finding more effective options for pediatric patients with serious immune-related illnesses.
Neoplasms
The oncology portfolio at Hôpital Cardiologique - Institut Cœur Poumon includes studies in classical Hodgkin lymphoma, acute lymphoblastic leukemia, and anaplastic large cell lymphoma. Research is focused on testing whether newer cancer treatments can improve response rates and support better outcomes for children and young adults.
- Classical Hodgkin lymphoma in children and young adults
- CD22-positive relapsed or refractory acute lymphoblastic leukemia
- ALK-positive anaplastic large cell lymphoma in standard-risk pediatric patients
These trials are aimed at evaluating anti-cancer therapies, especially for patients whose disease has returned or is harder to treat.
Respiratory Tract Diseases
In the area of respiratory tract diseases, the site is studying asthma and pulmonary arterial hypertension, with a focus on children who continue to have symptoms despite standard treatment. The trials are intended to test new add-on therapies and improve long-term disease control.
- Asthma and recurrent severe wheezing in young children
- Pulmonary arterial hypertension in pediatric patients
- Evaluating whether new treatments can reduce flare-ups and slow progression
This work supports better breathing-related care for children with chronic and potentially serious respiratory conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 38 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Jeanne De Flandre
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN). | Janssen Cilag International | Phase III | Recruiting | Jul 2024 | — |
IMP list
lock Showing 1 of 38 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prednisolone | 2 | Unknown | 2019-09-19 | 2021-03-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.